-
H.C. Wainwright Downgrades United Therapeutics To Neutral
Wednesday, June 15, 2016 - 12:04pm | 315Read More...H.C. Wainwright & Co. analysts Andrew Fein and Emile Yu have downgraded the shares of United Therapeutics Corporation (NASDAQ: UTHR) to a Neutral rating, pointing out that the scales are tipping the other way. The brokerage also lowered its price objective to $95. "We see no short-term drivers...
-
Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'
Wednesday, June 1, 2016 - 12:10pm | 288Read More...H.C. Wainwright’s Swayampakula Ramakanth mentioned that CARDIOME PHARMA CORP (NASDAQ: CRME) “has an experienced in-hospital sales force and is developing a niche business model in the fragmented and difficult-to-operate $100B European hospital pharmacy market.” Ramakanth...
-
H.C. Wainwright Initiates Radius Health At Buy, $55 Target
Monday, May 23, 2016 - 10:11am | 202Read More...H.C. Wainwright & Co.'s Carol Ann Werther initiated Radius Health Inc (NASDAQ: RDUS) at Buy with a $55.00 price target. The company's lead product candidate is abaloparatide (ABL), which is currently under review in Europe and the United States. "We expect launches in 4Q16 and 1Q17," said...
-
HC Wainwright Upgrades Caladrius Biosciences To Buy, Sets $1.25 Price Target
Friday, April 29, 2016 - 10:16am | 267Read More...Caladrius Biosciences Inc (NASDAQ: CLBS) has recently entered into a global collaboration agreement with Hitachi Chemical Co. H.C. Wainwright’s Raghuram Selvaraju upgraded the rating on Caladrius Biosciences from Neutral to Buy, with a price target of $1.25. Selvaraju mentioned the...
-
H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare
Tuesday, March 15, 2016 - 10:40am | 259Read More...On Tuesday, H.C. Wainwright & Co. issued a company note on Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) after the company had a positive Phase 3 trial win in oncology, with a survival win in AML of their drug Vyxeos. After the news, analysts at H.C. Wainwright reiterated their Buy rating...
-
H.C. Wainwright Still Buying Amarin, Sees DMC Decision By Summer
Friday, February 26, 2016 - 10:55am | 286Read More...H.C. Wainwright's Andrew S. Fein reiterated a Buy rating on Amarin Corporation plc (ADR) (NASDAQ: AMRN), with a price target of $10. The DMC decision is expected July–August 2016, and Fein believes that the study is likely to be recommended to be continued as planned. However, management...
-
Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright
Wednesday, August 19, 2015 - 8:26am | 262Read More...In illiquid pre-market trading, Biocept Inc (NASDAQ: BIOC) was indicated 6 percent higher at $2.08 following a bullish note from H.C. Wainwright & Co. analyst Yi Chen. Chen, who has a Ph.D. in biochemistry, is optimistic on Biocept's liquid biopsy technology, which he said provides...
-
What's Happening At The ASCO Conference?
Wednesday, June 3, 2015 - 10:08am | 463Read More...In a report published Wednesday, H.C. Wainwright analyst Reni Benjamin said that this year’s American Association of Clinical Oncology (ASCO) conference, which was held in Chicago from May 29 to June 2, comprised of presentations that "potentially generate shareholder value for select...
-
H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy
Tuesday, April 7, 2015 - 1:37pm | 176Read More...H.C. Wainwright & Co. on Tuesday initiated coverage on Celladon Corp (NASDAQ: CLDN) after impressive clinical trial results for its gene therapy Mydicar. Wainwright rates Celladon as a Buy with a $31 price target. Analyst Ching-Yi Lin wrote, "Thus far, we believe that the clinical trial results...
-
H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE
Thursday, April 2, 2015 - 10:27am | 148Read More...In a report published Thursday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $6.00 price target on OXiGENE Inc. (NASDAQ: OXGN). In the report, H.C. Wainwright & Co. noted, "We are reiterating our Buy rating and 12-month target price of $6 based on a discounted P/E...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside
Tuesday, October 21, 2014 - 9:20am | 182Read More...In a report published Tuesday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and $4.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Oncothyreon Inc. with a Buy rating and a 12-month...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Finjan Holdings, Inc. On Multiple Positive Factors
Thursday, September 25, 2014 - 10:54am | 128Read More...In a report published Thursday, H.C. Wainwright & Co. analyst Amit Dayal initiated coverage on Finjan Holdings, Inc. (NASDAQ: FNJN) with a Buy rating and $5.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage on Finjan Holdings, Inc. (FNJN) with a Buy...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On PolyMet Mining Corp. (USA) On Large-Scale Minnesota Project
Monday, September 8, 2014 - 11:11am | 110Read More...In a report published Monday, H.C. Wainwright & Co. analyst Heiko F. Ihle initiated coverage on PolyMet Mining Corp. (USA) (NYSE: PLM) with a Buy rating and $2.10 price target. In the report, H.C. Wainwright & Co. noted, “PolyMet Mining is focused on the permitting and development of its...
-
Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation
Friday, September 5, 2014 - 9:43am | 161Read More...In a note released Friday morning, H.C. Wainwright analyst Andrew Fein initiated coverage of Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) with a Buy rating and a $12 price target. Fein's optimistic view for the stock is based on the company's "value driver" TH-302 being in...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change
Monday, August 18, 2014 - 9:12am | 224Read More...In a report published Monday, H.C. Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on MELA Sciences (NASDAQ: MELA) with a Buy rating and $4.50 price target. In the report, H.C. Wainwright & Co. noted, “MELA Sciences has developed a multi-spectral scanning device, MelaFind...
